| CTRI Number |
CTRI/2025/02/080636 [Registered on: 17/02/2025] Trial Registered Prospectively |
| Last Modified On: |
18/12/2024 |
| Post Graduate Thesis |
No |
| Type of Trial |
BA/BE |
|
Type of Study
|
|
| Study Design |
Randomized, Crossover Trial |
|
Public Title of Study
|
Bioequivalence study of Diosmin 450
mg + Hesperidin 50 mg film-coated tablet in healthy, adult human, subjects under fed conditions. |
|
Scientific Title of Study
|
An Open label, balanced, randomized, truncated, two treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study of Pilestop Tablet (Diosmin 450 mg + Hesperidin 50 mg film-coated tablet) by The ACME Laboratories Ltd., with Daflon 500 Tablet (Diosmin 450 mg + Hesperidin 50 mg film-coated tablet) of LES Laboratories Servier Industrie in healthy, adult human, subjects under fed
conditions. |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| ICBio/013/0424, Version: 00, Dated: 29 Apr 2024 |
Protocol Number |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Ankita Das |
| Designation |
Principal Investigator |
| Affiliation |
ICBio Clinical Research Private limited |
| Address |
Investigator Room No: 01, Ground floor, Clinical department, No. 2, ICBio tower II, Devi Circle, Yelahanka Main Road, Chikkabetahalli, Vidyaranyapura
Bangalore
KARNATAKA
560097
India |
| Phone |
8069423000 |
| Fax |
|
| Email |
headcl@icbiocro.com |
|
Details of Contact Person
Scientific Query
|
| Name |
Dr Harish S |
| Designation |
Director |
| Affiliation |
ICBio Clinical Research Private limited |
| Address |
5 th floor, Room No: 01, Director Cabin, No. 2, ICBio Tower-II, Devi Circle chikkabettahalli, Yelahanka Main Road, vidyaranapura
Bangalore
KARNATAKA
560097
India |
| Phone |
09900111997 |
| Fax |
|
| Email |
harish@icbiocro.com |
|
Details of Contact Person
Public Query
|
| Name |
Dr Harish S |
| Designation |
Director |
| Affiliation |
ICBio Clinical Research Private limited |
| Address |
5 th floor, Room No: 01, Director Cabin, No. 2, ICBio Tower-II, Devi Circle chikkabettahalli, Yelahanka Main Road, vidyaranapura
KARNATAKA
560097
India |
| Phone |
09900111997 |
| Fax |
|
| Email |
harish@icbiocro.com |
|
|
Source of Monetary or Material Support
|
| M/s Icbio Clinical Research Pvt. Ltd, NO. 16 ICBio Tower,
Chikkabettahalli, Yelahanka Main Road, Vidyaranyapura, Bangalore (India) - 560097 |
|
|
Primary Sponsor
|
| Name |
The ACME Laboratories Ltd., |
| Address |
Court de la ACME 1/4, Kallayanpur, Mirpur road,
Dhaka- 1207, Bangladesh. |
| Type of Sponsor |
Pharmaceutical industry-Indian |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Ankita Das |
ICBio Clinical Research Private limited |
Investigator Room No: 01, Ground floor, Clinical department, No 2, Survey No 8/1/2 ICBio tower II, Devi Circle, Yelahanka Main Road
Bangalore
KARNATAKA |
8069423000
headcl@icbiocro.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| ACE Independent Ethics Committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Healthy Human Volunteers |
Fed condition |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
Daflon 500 Tablet (Diosmin 450 mg + Hesperidin 50 mg film-coated tablet) |
Name of the drug: Daflon 500 Tablet (Diosmin 450 mg + Hesperidin 50 mg film-coated tablet), Route of administration: Oral, Frequency: single oral dose, Study duration:15 days |
| Intervention |
Pilestop Tablet (Diosmin 450
mg + Hesperidin 50 mg film-coated tablet) |
Name of the drug: Pilestop Tablet (Diosmin 450
mg + Hesperidin 50 mg film-coated tablet),
Route of administration: Oral, Frequency: single oral dose, Study duration:15 days |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
55.00 Year(s) |
| Gender |
Both |
| Details |
1. Able to comprehend the nature and purpose of the study and willing to give written informed consent for participation in the study.
2. Willing to be available for the entire study period and to comply with protocol
requirements.
3. Normal, healthy, adult, human subject of 18-55 years (both inclusive) of age.
4. Body mass index in the range of 18.5 – 30.0 kg/m2 (both inclusive).
5. Healthy volunteers who are clinically non-anemic will be included as per the discretion of PI/CI/Physician. |
|
| ExclusionCriteria |
| Details |
1. Any medical or surgical condition, which might significantly interfere with the functioning of the gastrointestinal tract or blood–forming organs.
2. History or presence of gastric or duodenal ulcer or GI bleeding or blood in stools anytime in the past.
3. History of severe infection or major surgery in the past 6 months.
4. History of Minor surgery or fracture within the past 3 months.
5. Significant history or current evidence of malignancy or chronic - infectious, cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic (endocrine), hematological, gastrointestinal, immunological or psychiatric diseases, or organ dysfunction. |
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Pharmacy-controlled Randomization |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To evaluate Pharmacokinetics parameters: Cmax and AUC0-72 |
From Day 01 to Day 15 |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To evaluate Pharmacokinetics parameters: Tmax, λz and t1/2 |
From Day 01 to Day 15 |
|
|
Target Sample Size
|
Total Sample Size="24"
Sample Size from India="24"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
17/02/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="0"
Months="0"
Days="15" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
STUDY TITLE:An Open label, balanced, randomized, truncated, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study of Pilestop Tablet (Diosmin 450 mg + Hesperidin 50 mg film-coated tablet) by The ACME Laboratories Ltd., with Daflon 500 Tablet (Diosmin 450 mg + Hesperidin 50 mg film-coated tablet) of LES Laboratories Servier Industrie in healthy, adult, human subjects, under fed conditions.
OBJECTIVES:
Primary objective: To compare the rate and extent of absorption of Pilestop Tablet (Diosmin 450 mg + Hesperidin 50 mg film-coated tablet) by The ACME Laboratories Ltd., with Daflon 500 Tablet (Diosmin 450 mg + Hesperidin 50 mg film-coated tablet) of LES Laboratories Servier Industrie in healthy, adult, human subjects, under fed conditions.
Secondary objective: To monitor the safety and tolerability of the study subjects after administration of Pilestop Tablet (Diosmin 450 mg + Hesperidin 50 mg film-coated tablet) in healthy, adult, human subjects, under fed condition.
Number of subjects: Twenty-four (24) subjects Duration of clinical study: 15 days |